20 results
6-K
EX-99
GLPG
Galapagos NV
4 Apr 17
Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
12:00am
. or placebo q.d. administered for 12 weeks. TORTUGA will recruit in 8 European countries.
The primary goal of TORTUGA will be to evaluate the effect … . administered for 16 weeks. EQUATOR will recruit in 8 European countries.
Primary goal of EQUATOR will be to evaluate the effect of filgotinib compared
6-K
EX-99.1
GLPG
Galapagos NV
7 Jan 19
Current report (foreign)
7:29am
in patients with systemic sclerosis (SSc, or scleroderma). NOVESA is planned to recruit 30 patients with diffuse cutaneous SSc, an autoimmune disease involving
6-K
EX-99.1
GLPG
Galapagos NV
24 Sep 18
Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients
6:05am
once-daily doses of GLPG1972/S201086 in patients with knee osteoarthritis (OA). ROCCELLA is planned to recruit approximately 850 patients in countries
6-K
EX-99.1
GLPG
Galapagos NV
28 Nov 18
Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
6:00am
osteoarthritis. ROCCELLA is planned to recruit approximately 850 patients in up to 15 countries. Galapagos will be responsible for ROCCELLA
6-K
EX-99.1
GLPG
Galapagos NV
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
, with the aim to recruit the first patients around year-end
Corporate update
Received various transparency notifications from FMR LLC, indicating that its … following the PRAC Article 20 recommendation issued on 28 October 2022.
We aim to recruit the first patients in a Phase 2 study of our TYK2 inhibitor
6-K
EX-99.1
9itcx
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
6-K
EX-99.1
1pl4ze
27 Jun 18
Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients
6:01am
6-K
EX-99.15
calmnep
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.2
pdv grilv
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
ebx up3q4cautruizuob
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
6-K
EX-99.2
w83 kl2y0z
6 Aug 20
Galapagos reports solid H1 2020 progress
4:01pm
6-K
EX-99.3
j8618t
11 May 21
Current report (foreign)
2:10pm
20-F
3rb6adh1e924
25 Mar 16
Annual report (foreign)
12:00am
- Prev
- 1
- Next